H9-KGDEVD-MMAE 

H9-KGDEVD-MMAE is an antibody-drug conjugate that specifically binds to PRND to enable precise drug delivery to tumor vasculature and cancer cells. H9-KGDEVD-MMAE contains a linker cleavable by cathepsin B and caspase-3/7, allowing the release of MMAE in lysosomes. H9-KGDEVD-MMAE induces apoptosis, produces a bystander effect, and disrupts tumor vasculature. H9-KGDEVD-MMAE achieves deep tumor penetration and exhibits durable anti-tumor efficacy without systemic toxicity in preclinical models of highly vascularized malignant tumors. H9-KGDEVD-MMAE can be applied to research related to glioblastoma, sarcoma, and renal cell carcinoma^[1].

1746.00

C₈₅H₁₂₈N₁₄O₂₅

1932672-71-3

CC(N[C@@H](CCCCNC(CCCCCN1C(C=CC1=O)=O)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(O)=O)C(NC2=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N3[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C4=CC=CC=C4)=O)CCC3)=O)=O)=O)=O)C=C2)=O)=O)=O)=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kim B, Lee H K, Choi S Y, et al. Tumor endothelial cell and cancer cell targeting anti-PRND antibody-drug conjugate to treat hypervascular tumors such as glioblastoma and sarcomas[J]. Cancer Research, 2026, 86(7_Supplement): 2649-2649.